On Friday, C4 Therapeutics Inc (NASDAQ: CCCC) was 0.73% up from the session before settling in for the closing price of $1.37. A 52-week range for CCCC has been $1.09 – $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 19.86% over the last five years. When this article was written, the company’s average yearly earnings per share was at -11.89%. With a float of $54.24 million, this company’s outstanding shares have now reached $70.99 million.
The firm has a total of 110 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.25%, operating margin of -292.99%, and the pretax margin is -259.27%.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 23.61%, while institutional ownership is 80.35%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -11.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.55% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.53 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Analysing the last 5-days average volume posted by the [C4 Therapeutics Inc, CCCC], we can find that recorded value of 1.02 million was lower than the volume posted last year of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 21.08%. Additionally, its Average True Range was 0.15.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 9.15%, which indicates a significant decrease from 20.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.68% in the past 14 days, which was higher than the 87.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5720, while its 200-day Moving Average is $3.9207. Now, the first resistance to watch is $1.4000. This is followed by the second major resistance level at $1.4200. The third major resistance level sits at $1.4600. If the price goes on to break the first support level at $1.3400, it is likely to go to the next support level at $1.3000. Now, if the price goes above the second support level, the third support stands at $1.2800.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 71,007K outstanding shares of the company, which has a market capitalization of 97.99 million. As of now, sales total 35,580 K while income totals -105,320 K. Its latest quarter income was 7,240 K while its last quarter net income were -26,320 K.
